PMID- 26059424
OWN - NLM
STAT- MEDLINE
DCOM- 20161017
LR  - 20220330
IS  - 1651-2057 (Electronic)
IS  - 0001-5555 (Linking)
VI  - 96
IP  - 1
DP  - 2016 Jan
TI  - Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption 
      and Omalizumab.
PG  - 72-6
LID - 10.2340/00015555-2165 [doi]
AB  - Patients with atopic dermatitis (AD) tend to have greatly elevated levels of 
      serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD 
      is debated. This investigator-initiated open-label pilot study evaluates an 
      anti-IgE-treatment approach by combining extracorporeal immunoadsorption and 
      anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. 
      IgE levels decreased after immunoadsorption and decreased continuously in all 
      patients during anti-IgE therapy. The reverse trend was observed during 6 months 
      follow-up without treatment. In parallel with these observations, an improvement 
      in AD was observed during the treatment period, with aggravation during 
      follow-up. Further research is needed, based on the principle of reducing IgE 
      levels in order to improve clinical symptoms, using a combination anti-IgE 
      treatment approach, adjusted according to IgE levels.
FAU - Zink, Alexander
AU  - Zink A
AD  - Department of Dermatology and Allergy, Technische Universitat Munchen (TUM), 
      Biedersteiner Str. 29, DE-80802 Munich, Germany. zink@lrz.tum.de.
FAU - Gensbaur, Anna
AU  - Gensbaur A
FAU - Zirbs, Michael
AU  - Zirbs M
FAU - Seifert, Florian
AU  - Seifert F
FAU - Suarez, Isabel Leon
AU  - Suarez IL
FAU - Mourantchanian, Vagkan
AU  - Mourantchanian V
FAU - Weidinger, Stephan
AU  - Weidinger S
FAU - Mempel, Martin
AU  - Mempel M
FAU - Ring, Johannes
AU  - Ring J
FAU - Ollert, Markus
AU  - Ollert M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Biomarkers)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Allergic Agents/adverse effects/*therapeutic use
MH  - Biomarkers/blood
MH  - *Blood Component Removal/adverse effects
MH  - Combined Modality Therapy
MH  - Dermatitis, Atopic/blood/diagnosis/immunology/*therapy
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - *Immunosorbent Techniques/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Omalizumab/adverse effects/*therapeutic use
MH  - Pilot Projects
MH  - Remission Induction
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2015/06/11 06:00
MHDA- 2016/10/19 06:00
CRDT- 2015/06/11 06:00
PHST- 2015/06/11 06:00 [entrez]
PHST- 2015/06/11 06:00 [pubmed]
PHST- 2016/10/19 06:00 [medline]
AID - 10.2340/00015555-2165 [doi]
PST - ppublish
SO  - Acta Derm Venereol. 2016 Jan;96(1):72-6. doi: 10.2340/00015555-2165.